<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178400">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772668</url>
  </required_header>
  <id_info>
    <org_study_id>20070963</org_study_id>
    <secondary_id>SCCC-2006120</secondary_id>
    <nct_id>NCT00772668</nct_id>
  </id_info>
  <brief_title>Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Treating Patients With Stage III or Stage IV Follicular Lymphoma or Marginal Zone Lymphoma</brief_title>
  <official_title>Pilot Study of RCVELP as First Line Therapy for Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells
      and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy,
      such as cyclophosphamide and prednisone, work in different ways to stop the growth of cancer
      cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop
      the growth of cancer cells by blocking some of the enzymes needed for cell growth and by
      blocking blood flow to the tumor. Giving rituximab together with cyclophosphamide,
      bortezomib, and prednisone may kill more cancer cells.

      PURPOSE: This clinical trial is studying how well giving rituximab together with
      cyclophosphamide, bortezomib, and prednisone works as first-line therapy in treating
      patients with stage III or stage IV follicular lymphoma or marginal zone lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the overall response rate, in terms of complete response (CR), unconfirmed
           CR, and partial response, in patients with follicular lymphoma or marginal zone
           lymphoma treated with rituximab, cyclophosphamide, bortezomib, and prednisone (R-CVelP)
           as first line of treatment.

      Secondary

        -  To determine progression-free survival of patients treated with this regimen.

        -  To determine overall survival of patients treated with this regimen.

        -  To determine the safety and tolerance to R-CVelP in these patients.

      OUTLINE:

        -  Induction therapy: Patients receive rituximab IV and cyclophosphamide IV over 30
           minutes on day 1, bortezomib IV on days 1 and 8, and oral prednisone once daily on days
           1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease
           progression or unacceptable toxicity. Patients then proceed to maintenance therapy.

        -  Maintenance therapy: Patients receive rituximab IV on days 1, 8, 15, and 22. Treatment
           repeats every 6 months for up to 4 courses in the absence of disease progression or
           unacceptable toxicity.

      After completion of study therapy, patients are followed every 4 months for 1 year, every 6
      months for 2 years, and then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate, According to the International Workshop Criteria (IWC)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival as Assessed by RECIST Criteria</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerance to Rituximab, Cyclophosphamide, Bortezomib, and Prednisone</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>RCVELP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles</description>
    <arm_group_label>RCVELP</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles</description>
    <arm_group_label>RCVELP</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles</description>
    <arm_group_label>RCVELP</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles</description>
    <arm_group_label>RCVELP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed grade 1 or 2 follicular lymphoma (FL) or marginal zone
             lymphoma (MZL)

               -  Stage III or IV disease

          -  Measurable or evaluable disease

          -  Previously untreated disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 1-3

          -  ANC &gt; 1,000/mm³

          -  Platelet count &gt; 100,000/mm³ (unless due to lymphoma)

          -  Bilirubin &lt; 2.0 mg/dL

          -  Creatinine &lt; 2 mg/dL (unless due to lymphoma)

          -  AST, ALT, and alkaline phosphatase &lt; 3 times upper limit of normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No myocardial infarction within the past 6 months

          -  No NYHA class III-IV heart failure

          -  No uncontrolled angina

          -  No severe uncontrolled ventricular arrhythmias

          -  No ECG evidence of acute ischemia or active conductive system abnormalities

          -  No hypersensitivity to boron or mannitol

          -  No serious medical or psychiatric illness likely to interfere with participation in
             this clinical study

          -  No history of HIV infection

          -  No concurrent or previous malignancy with poor prognosis (&lt; 90% probability of
             survival at 5 years) or actively treated for a second malignancy

          -  No peripheral neuropathy ≥ grade 2 within the past 14 days

        PRIOR CONCURRENT THERAPY:

          -  No prior therapy for this disease including chemotherapy, single-agent rituximab, or
             radiotherapy

          -  No other concurrent anticancer therapy including chemotherapy, radiation, hormonal
             treatment, or immunotherapy

          -  At least 14 days since prior and no other concurrent investigational drugs

          -  No concurrent participation in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Pereira, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 14, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2008</firstreceived_date>
  <firstreceived_results_date>January 18, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RCVELP</title>
          <description>Bortezomib : 1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles
Cyclophosphamide : 750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles
Prednisone : 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles
Rituximab : 375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RCVELP</title>
          <description>Bortezomib : 1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles
Cyclophosphamide : 750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles
Prednisone : 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles
Rituximab : 375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate, According to the International Workshop Criteria (IWC)</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RCVELP</title>
            <description>Bortezomib : 1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles
Cyclophosphamide : 750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles
Prednisone : 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles
Rituximab : 375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate, According to the International Workshop Criteria (IWC)</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival as Assessed by RECIST Criteria</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerance to Rituximab, Cyclophosphamide, Bortezomib, and Prednisone</title>
        <time_frame>5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No serious or non-serious adverse events were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>RCVELP</title>
          <description>Bortezomib : 1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles
Cyclophosphamide : 750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles
Prednisone : 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles
Rituximab : 375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early due to lack of funding. All patients were removed from the study. No results were analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Denise Pereira MD</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer</organization>
      <phone>305-243-9127</phone>
      <email>dpereira2@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
